CLZ-2002 / Cellatoz Therap - LARVOL DELTA

CLZ-CMT-101: The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease. (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Cellatoz Therapeutics, Inc | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders

Peripheral Nerve Remyelination and Restoration of Neuro-Muscular Function by Allogeneic Schwann Cell-like Therapy: Preclinical Models of Charcot-Marie-Tooth Type 1 Neuropathy and Phase 1 Trial in CMT1 Patients. (ASGCT 2024) - "Allogeneic CLZ-2002 therefore represents an innovative scientific and logistical approach to intervene in the progression of disability associated with peripheral neuropathy. Based on this positive preclinical data, CLZ-2002 was progressed to a Phase 1, open-label, prospective, dose-finding study for the evaluation of safety and tolerability of intramuscular injections of CLZ-2002 in patients with Charcot-Marie- Tooth Type 1 disease."

Late-breaking abstract • P1 data • Preclinical • Genetic Disorders • Infectious Disease • Mood Disorders • Pain • Peripheral Neuropathic Pain

The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease. (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Cellatoz Therapeutics, Inc | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2024 ➔ Jul 2024

Enrollment closed • Trial completion date • Genetic Disorders

The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease. (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Cellatoz Therapeutics, Inc

New P1 trial • Genetic Disorders